日期:
2020 年 — 2026 年
2020
2021
2022
2023
2024
2025
2026
影响因子:

Targeted Delivery of a Potent STING Agonist Payload via an Antibody-Drug Conjugate Drives Robust Antitumor Activity in Preclinical Models

通过抗体-药物偶联物靶向递送强效STING激动剂有效载荷,在临床前模型中展现出强大的抗肿瘤活性

Gruber, David R; Cummins, Elizabeth J; Zeng, Weiping; Ulrich, Michelle; Smith, Kaleb; Long, Mallory; Spahr, Kellie; Higgins, Shaylin; Hinricher, Katelyn; Langalia, Aditi; Krumm, Kora; Olson, Devra J; Grogan, Bryan; Mazahreh, Rebecca; Gupta, Priyanka; Burke, Patrick J; Smith, Alyson; Senter, Peter D; Gardai, Shyra J; Hill, Adam G; Gray, Elizabeth E

SGN-CD228A Is an Investigational CD228-Directed Antibody-Drug Conjugate with Potent Antitumor Activity across a Wide Spectrum of Preclinical Solid Tumor Models

SGN-CD228A 是一种在研的 CD228 靶向抗体药物偶联物,在多种临床前实体瘤模型中均表现出强大的抗肿瘤活性。

Rebecca Mazahreh # ,Marsha L Mason # ,John J Gosink ,Devra J Olson ,Robert Thurman ,Christopher Hale ,Lori Westendorf ,Thomas A Pires ,Christopher I Leiske ,Markus Carlson ,Liem T Nguyen ,Julia H Cochran ,Nicole M Okeley ,Roma Yumul ,Steven Jin ,Ivan J Stone ,Disha Sahetya ,Albina Nesterova ,Sean Allred ,Kelly M Hensley ,Rachael Hu ,Robert Lawrence ,Timothy S Lewis ,Sharsti Sandall